Skip to Content

Prestige Consumer Healthcare Inc

PBH: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$71.00SkjrbqnDtzgctj

We Think Prestige Consumer Healthcare Is Small but Mighty, Boasting Leadership in Niche Markets

Business Strategy and Outlook

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers in the U.S. We expect the firm to grow through product innovations, increasing household penetration, and expanding its e-commerce presence. One way Prestige has tackled product innovations is through broadening its brands’ end markets; for example, Dramamine for a long time only played in the motion sickness space, but Prestige has spent the last number of years expanding its indication to the nausea market. While these outbreaks of categories can certainly expose Prestige to new competition, we believe it also affords the firm a new set of customers that it can win over. And given Prestige’s focus in small and niche categories, we don’t expect the company to try and compete with blockbuster brands from consumer packaged goods, or CPG, giants. Rather, we believe it will seek out adjacent categories that might be underpenetrated or composed of minor brands to displace with its recognizable brands.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of PBH so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center